• Sonoma Pharmaceuticals posted a net loss of USD 330,000 for the quarter ended June 30, 2026, narrowing from USD 1.24 million.
• Revenue rose 60% to USD 6.41 million, led by the United States where revenue more than doubled to USD 2.43 million.
• Gross profit climbed 76% to USD 2.58 million; gross margin widened 4 percentage points to 40% on manufacturing improvements and customer mix.
• Cash and cash equivalents increased to USD 5.34 million at June 30 from USD 2.4 million at March 31, helped by USD 3.45 million in financing cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006024), on August 06, 2026, and is solely responsible for the information contained therein.